{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:17Z","timestamp":1792098557514,"version":"4.4.0"},"reference-count":111,"publisher":"Elsevier","isbn-type":[{"value":"9780128177822","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.vh.2018.10.002","type":"book-chapter","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T02:58:43Z","timestamp":1545361123000},"page":"211-239","source":"Crossref","is-referenced-by-count":24,"title":["Inhibitors of Aldosterone Synthase"],"prefix":"10.1016","author":[{"given":"Steven M.","family":"Weldon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.vh.2018.10.002_bb0010","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1095\/biolreprod59.6.1399","article-title":"Expression and possible role of muscle-type carnitine palmitoyltransferase I during sperm development in the rat","volume":"59","author":"Adams","year":"1998","journal-title":"Biology of Reproduction"},{"key":"10.1016\/bs.vh.2018.10.002_bb0015","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.bmcl.2010.06.086","article-title":"The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase","volume":"20","author":"Adams","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fchem.2017.00104","article-title":"Pharmacophore modeling and in silico\/in vitro screening for human cytochrome P450 11B1 and cytochrome P450 11B2 inhibitors","volume":"5","author":"Akram","year":"2017","journal-title":"Frontiers in Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/HJH.0b013e32835d6d49","article-title":"Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism","volume":"31","author":"Amar","year":"2013","journal-title":"Journal of Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: A proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1751-7176.2012.00667.x","article-title":"The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: A phase II, randomized, double-blind, placebo-controlled, multicenter study","volume":"14","author":"Andersen","year":"2012","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"key":"10.1016\/bs.vh.2018.10.002_bb0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/bs.vh.2018.10.002_bb0045","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/bs.vh.2018.10.002_bb0050","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.1073\/pnas.95.16.9424","article-title":"Mineralocorticoid receptor knockout mice: Pathophysiology of Na+ metabolism","volume":"95","author":"Berger","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.vh.2018.10.002_bb0055","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: Results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2018.10.002_bb0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0065","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nature Clinical Practice. Nephrology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: Effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000345243","article-title":"Vascular actions of aldosterone","volume":"50","author":"Briet","year":"2013","journal-title":"Journal of Vascular Research"},{"key":"10.1016\/bs.vh.2018.10.002_bb0080","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0085","first-page":"A135","article-title":"Sustained, selective aldosterone synthase (AS) inhibition in cynomolgus primates: Effects of 7-day repeat dosing on plasma K+ and steroid profile","volume":"65","author":"Brown","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/bs.vh.2018.10.002_bb0090","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/bi0157870","article-title":"Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1","volume":"41","author":"Bureik","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.vascn.2014.09.011","article-title":"Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors","volume":"71","author":"Cai","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/bs.vh.2018.10.002_bb0100","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/bs.vh.2018.10.002_bb0105","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026611313120003","article-title":"Progress towards clinically useful aldosterone synthase inhibitors","volume":"13","author":"Cerny","year":"2013","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jsbmb.2015.08.004","article-title":"Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human","volume":"154","author":"Cerny","year":"2015","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gene.2013.08.047","article-title":"Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms","volume":"531","author":"Chen","year":"2013","journal-title":"Gene"},{"key":"10.1016\/bs.vh.2018.10.002_bb0120","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney International"},{"key":"10.1016\/bs.vh.2018.10.002_bb0125","first-page":"1162","article-title":"The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis","volume":"70","author":"Demers","year":"1990","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2018.10.002_bb0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.mce.2011.07.019","article-title":"Non-genomic actions of aldosterone: From receptors and signals to membrane targets","volume":"350","author":"Dooley","year":"2012","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12032-007-9019-x","article-title":"Aromatase inhibitors: Past, present and future in breast cancer therapy","volume":"25","author":"Dutta","year":"2008","journal-title":"Medical Oncology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0960-0760(02)00056-0","article-title":"Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening in fission yeast and evaluation of selectivity in V79 cells","volume":"81","author":"Ehmer","year":"2002","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0145","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0150","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/1440-1681.12157","article-title":"Vascular effects of aldosterone: Sorting out the receptors and the ligands","volume":"40","author":"Feldman","year":"2013","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0155","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/bs.vh.2018.10.002_bb0160","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/bs.vh.2018.10.002_bb0165","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejphar.2016.11.049","article-title":"A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure","volume":"795","author":"Furuzono","year":"2017","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0170","first-page":"5488","article-title":"Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis","volume":"50","author":"Gazdar","year":"1990","journal-title":"Cancer Research"},{"key":"10.1016\/bs.vh.2018.10.002_bb0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"key":"10.1016\/bs.vh.2018.10.002_bb0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mce.2013.11.022","article-title":"Development of monoclonal antibodies against human CYP11B1 and CYP11B2","volume":"383","author":"Gomez-Sanchez","year":"2014","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0185","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/01.HYP.0000259797.48382.b2","article-title":"Nongenomic actions of aldosterone on the renal tubule","volume":"49","author":"Good","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0190","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/pgmj.45.523.307","article-title":"Criteria for distinguishing normal from subnormal adrenocortical function using the Synacthen test","volume":"45","author":"Greig","year":"1969","journal-title":"Postgraduate Medical Journal"},{"key":"10.1016\/bs.vh.2018.10.002_bb0195","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ejmech.2014.10.027","article-title":"1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: A new class of potent and selective aldosterone synthase inhibitors","volume":"89","author":"Grombein","year":"2015","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0200","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ejmech.2014.12.022","article-title":"Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase","volume":"90","author":"Grombein","year":"2015","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0205","doi-asserted-by":"crossref","first-page":"C532","DOI":"10.1152\/ajpcell.00203.2012","article-title":"Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation","volume":"304","author":"Gros","year":"2013","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","article-title":"New aspects of rapid aldosterone signaling","volume":"308","author":"Grossmann","year":"2009","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0215","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jsbmb.2010.12.011","volume":"125","author":"Hakki","year":"2011","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0220","series-title":"Goodman and Gillman's the pharmacological basis of therapeutics","year":"2001"},{"key":"10.1016\/bs.vh.2018.10.002_bb0225","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0223-5234(03)00049-7","article-title":"Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis","volume":"38","author":"Hartmann","year":"2003","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0235","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1021\/jm800377h","article-title":"Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: Influence of heteroaryl derivatization on potency and selectivity","volume":"51","author":"Heim","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsbmb.2012.03.002","article-title":"Human aldosterone synthase: Recombinant expression in E. coli and purification enables a detailed biochemical analysis of the protein on the molecular level","volume":"132","author":"Hobler","year":"2012","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0245","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1210\/en.2016-1358","article-title":"Aldosterone synthase inhibition improves glucose tolerance in Zucker diabetic fatty (ZDF) rats","volume":"157","author":"Hofmann","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0250","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"14","author":"Hostetter","year":"2003","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1016\/bs.vh.2018.10.002_bb0255","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acsmedchemlett.5b00054","article-title":"Discovery of benzimidazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys","volume":"6","author":"Hoyt","year":"2015","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0260","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/acsmedchemlett.5b00048","article-title":"Discovery of triazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys","volume":"6","author":"Hoyt","year":"2015","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0265","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.bmcl.2017.04.021","article-title":"Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension","volume":"27","author":"Hoyt","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0270","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1021\/jm401430e","article-title":"Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases","volume":"57","author":"Hu","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0275","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","article-title":"Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt","volume":"126","author":"Kagawa","year":"1957","journal-title":"Science (New York, NY)"},{"key":"10.1016\/bs.vh.2018.10.002_bb0280","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"key":"10.1016\/bs.vh.2018.10.002_bb0285","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0014-5793(90)81190-Y","article-title":"Cloning of cDNA and genomic DNA for human cytochrome P-45011 beta","volume":"269","author":"Kawamoto","year":"1990","journal-title":"FEBS Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0290","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1161\/HYPERTENSIONAHA.110.159459","article-title":"Cell membrane-associated mineralocorticoid receptors? New evidence","volume":"57","author":"Krug","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0295","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-69-4-896","article-title":"The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro","volume":"69","author":"Lamberts","year":"1989","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2018.10.002_bb0300","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: Third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.vh.2018.10.002_bb0305","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.1021\/jm800683c","article-title":"Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach","volume":"51","author":"Lucas","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0310","doi-asserted-by":"crossref","first-page":"8077","DOI":"10.1021\/jm800888q","article-title":"In vivo active aldosterone synthase inhibitors with improved selectivity: Lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives","volume":"51","author":"Lucas","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0315","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1021\/jm101470k","article-title":"Fine-tuning the selectivity of aldosterone synthase inhibitors: Structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives","volume":"54","author":"Lucas","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0320","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","article-title":"Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets","volume":"54","author":"Luther","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/bs.vh.2018.10.002_bb0325","doi-asserted-by":"crossref","first-page":"F61","DOI":"10.1152\/ajprenal.00257.2005","article-title":"Kidney function in mice lacking aldosterone","volume":"290","author":"Makhanova","year":"2006","journal-title":"American Journal of Physiology. Renal Physiology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0330","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/01.HYP.0000249902.09036.e7","article-title":"Disturbed homeostasis in sodium-restricted mice heterozygous and homozygous for aldosterone synthase gene disruption","volume":"48","author":"Makhanova","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0335","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/CS20070123","article-title":"Aldosterone and end-organ damage","volume":"113","author":"Marney","year":"2007","journal-title":"Clinical Science (London, England)"},{"key":"10.1016\/bs.vh.2018.10.002_bb0340","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.5b00851","article-title":"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: In vivo evaluation in rodents and cynomolgus monkeys","volume":"58","author":"Martin","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0345","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1039\/C6OB00848H","article-title":"Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2)","volume":"14","author":"Martin","year":"2016","journal-title":"Organic & Biomolecular Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0350","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.bmcl.2017.03.034","article-title":"4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures","volume":"27","author":"Meguro","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0355","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.hjh.0000226205.65442.f2","article-title":"Investigation of aldosterone-synthase inhibition in rats","volume":"24","author":"Menard","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0360","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.hjh.0000226183.98439.b3","article-title":"Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?","volume":"24","author":"Menard","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0365","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12967-014-0340-9","article-title":"Aldosterone synthase inhibition: Cardiorenal protection in animal disease models and translation of hormonal effects to human subjects","volume":"12","author":"Menard","year":"2014","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/bs.vh.2018.10.002_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(10)60584-0","article-title":"Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy adults","volume":"55","author":"Menard","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0375","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/ml400324c","article-title":"Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors","volume":"4","author":"Meredith","year":"2013","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0380","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bmcl.2017.12.015","article-title":"Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity","volume":"28","author":"Meyers","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0385","doi-asserted-by":"crossref","first-page":"20961","DOI":"10.1016\/S0021-9258(19)30030-4","article-title":"Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta)","volume":"264","author":"Mornet","year":"1989","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0390","first-page":"e38","article-title":"Heart disease and stroke statistics-2016 update: A report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/bs.vh.2018.10.002_bb0395","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jsbmb.2005.04.032","article-title":"The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors","volume":"96","author":"Muller-Vieira","year":"2005","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"Suppl. 1","key":"10.1016\/bs.vh.2018.10.002_bb0400","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ndt\/gft402","article-title":"Aldosterone synthase inhibitors in cardiovascular and renal diseases","volume":"29","author":"Namsolleck","year":"2014","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/bs.vh.2018.10.002_bb0405","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1021\/acs.jmedchem.5b00407","article-title":"Structure-activity relationships, pharmacokinetics, and in vivo activity of CYP11B2 and CYP11B1 inhibitors","volume":"58","author":"Papillon","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0410","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1021\/acs.jmedchem.5b01545","article-title":"Discovery of N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonam ide, a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects","volume":"58","author":"Papillon","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0415","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/acsmedchemlett.6b00455","article-title":"Discovery of spirocyclic aldosterone synthase inhibitors as potential treatments for resistant hypertension","volume":"8","author":"Petrilli","year":"2017","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0420","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.vh.2018.10.002_bb0425","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1016\/bs.vh.2018.10.002_bb0430","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.vh.2018.10.002_bb0435","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES])","volume":"78","author":"RALES","year":"1996","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0440","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jsbmb.2009.04.013","article-title":"Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo","volume":"116","author":"Ries","year":"2009","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0445","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.110.167148","article-title":"Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: Comparison with the 11beta-hydroxylase inhibitor metyrapone","volume":"334","author":"Rigel","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.vh.2018.10.002_bb0450","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1021\/jm901356d","article-title":"Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2)","volume":"53","author":"Roumen","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0455","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem-73-1-99","article-title":"Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor","volume":"73","author":"Santen","year":"1991","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2018.10.002_bb0460","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.HYP.0000083298.23119.16","article-title":"Rapid nongenomic effects of aldosterone on human forearm vasculature","volume":"42","author":"Schmidt","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/bs.vh.2018.10.002_bb0465","doi-asserted-by":"crossref","first-page":"11775","DOI":"10.1073\/pnas.1004250107","article-title":"Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe\/S cluster biosynthesis","volume":"107","author":"Sheftel","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.vh.2018.10.002_bb0470","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"American Journal of Nephrology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0475","doi-asserted-by":"crossref","DOI":"10.1177\/1470320317717883","article-title":"LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase","volume":"18","author":"Sloan-Lancaster","year":"2017","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System: JRAAS"},{"key":"10.1016\/bs.vh.2018.10.002_bb0480","first-page":"571","article-title":"The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects","volume":"74","author":"Trunet","year":"1992","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2018.10.002_bb0485","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1021\/jm0492397","article-title":"Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes\/\u2212indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase","volume":"48","author":"Ulmschneider","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0490","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1021\/jm049600p","article-title":"Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: Potent inhibitors of aldosterone synthase","volume":"48","author":"Ulmschneider","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0495","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bmcl.2005.09.059","article-title":"Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2)","volume":"16","author":"Ulmschneider","year":"2006","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0500","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","article-title":"The role of the renin-angiotensin system in the development of cardiovascular disease","volume":"89","author":"Unger","year":"2002","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/bs.vh.2018.10.002_bb0505","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0024-3205(92)90204-3","article-title":"Adrenal glands of mouse and rat do not synthesize androgens","volume":"50","author":"van Weerden","year":"1992","journal-title":"Life Sciences"},{"key":"10.1016\/bs.vh.2018.10.002_bb0510","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1021\/jm060055x","article-title":"Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: Potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis","volume":"49","author":"Voets","year":"2006","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0515","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ardp.200400872","article-title":"Synthesis of amidinohydrazones and evaluation of their inhibitory effect towards aldosterone synthase (CYP11B2) and the formation of selected steroids","volume":"337","author":"Voets","year":"2004","journal-title":"Archiv der Pharmazie"},{"key":"10.1016\/bs.vh.2018.10.002_bb0520","first-page":"296","article-title":"Efficacy and safety of LCI699 for hypertension: A meta-analysis of randomized controlled trials and systematic review","volume":"19","author":"Wang","year":"2015","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1016\/bs.vh.2018.10.002_bb0525","first-page":"1","article-title":"Dysglycemia and dyslipidemia models in nonhuman primates: Part I. Model of naturally occurring diabetes","volume":"S13","author":"Wang","year":"2015","journal-title":"Journal of Diabetes & Metabolism"},{"key":"10.1016\/bs.vh.2018.10.002_bb0530","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.116.236463","article-title":"Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: Comparison with FAD286 and LCI699 in nonhuman primates","volume":"359","author":"Weldon","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.vh.2018.10.002_bb0535","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bmcl.2016.12.003","article-title":"Imidazopyridyl compounds as aldosterone synthase inhibitors","volume":"27","author":"Whitehead","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.002_bb0540","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MED.0b013e328360c200","article-title":"Evolving research in nongenomic actions of aldosterone","volume":"20","author":"Williams","year":"2013","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"key":"10.1016\/bs.vh.2018.10.002_bb0545","series-title":"Cardiovascular disease fact sheet","author":"World Health Organization","year":"2017"},{"key":"10.1016\/bs.vh.2018.10.002_bb0550","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1021\/jm500140c","article-title":"Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors","volume":"57","author":"Yin","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.002_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048048","article-title":"3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: Aromaticity abolishment of the core significantly increased selectivity over CYP1A2","volume":"7","author":"Yin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.vh.2018.10.002_bb0560","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bmcl.2010.11.040","article-title":"N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)","volume":"21","author":"Zimmer","year":"2011","journal-title":"Bioorganic & Medicinal Chemistry Letters"}],"container-title":["Vitamins and Hormones","Aldosterone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672918300748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672918300748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T22:27:56Z","timestamp":1662676076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0083672918300748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177822"],"references-count":111,"URL":"https:\/\/doi.org\/10.1016\/bs.vh.2018.10.002","relation":{},"ISSN":["0083-6729"],"issn-type":[{"value":"0083-6729","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}